UnitedHealth, FTC Near Settlement on Insulin Rebates
UnitedHealth Group and the Federal Trade Commission reached a tentative agreement as of June 12 to resolve allegations that the company's pharmacy benefit operations inflated insulin prices, according to Becker's Hospital Review. The settlement would cover Optum Rx, UnitedHealth's PBM, and its group purchasing organization, Emisar Pharma Services.
The FTC sued in 2024, arguing the country's three largest PBMs and their affiliated drug-buying groups had "created a broken rebate system that inflated insulin drug prices." The agency's core claim is that PBMs steered patients toward higher-priced insulins because those drugs generated larger rebates, leaving some patients paying more at the pharmacy counter. Optum Rx and Emisar were one of three sets of defendants named in the complaint.
A settlement with UnitedHealth would mark a notable step in the FTC's broader scrutiny of PBM pricing practices. It also signals how regulators intend to police the rebate-driven middle of the drug supply chain, a structure long criticized for obscuring true drug costs from patients and employers.
Sources